Publications by authors named "Beatriz Baptista Olicheski"
Halofuginone for non-hospitalized adult patients with COVID-19 a multicenter, randomized placebo-controlled phase 2 trial. The HALOS trial.
Bruno Martins Tomazini Lucas Tramujas Fernando Azevedo Medrado Samara Pinheiro do Carmo Gomes Karina Leal Negrelli Beatriz Baptista Olicheski
PLoS One
February 2024
Background: Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent in vitro activity against SARS-CoV-2 virus. The safety and efficacy of halofuginone in Covid-19 patients has not been studied.
Methods: We conducted a phase II, randomized, double-blind, placebo-controlled, dose ranging, safety and tolerability trial of halofuginone in symptomatic (≤ 7 days), mostly vaccinated, non-hospitalized adults with mild to moderate Covid-19.